Alpha Tau Medical Ltd(DRTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 19.81% | Shs Outstand | 92.3M | Perf Week | -0.76% |
| Market Cap | 1.21B | Forward P/E | - | EPS next Y | 44.05% | Insider Trans | -0.72% | Shs Float | 74.2M | Perf Month | -9.99% |
| Enterprise Value | 1.12B | PEG | - | EPS next Q | -0.15 | Inst Own | 9.08% | Short Float | 4.63% | Perf Quarter | 9.56% |
| Income | -0.09B | P/S | - | EPS this Y | -80.61% | Inst Trans | 13.11% | Short Ratio | 6.51 | Perf Half Y | 52.93% |
| Sales | 0.00B | P/B | 27.37 | EPS next 5Y | 10.86% | ROA | -75.51% | Short Interest | 3.44M | Perf YTD | 163.84% |
| Book/sh | 0.48 | P/C | 11.53 | EPS past 3/5Y | 0.15% -19.21% | ROE | -141.68% | 52W High | -17.29% ($15.79) | Perf Year | 223.27% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -159.91% | 52W Low | 280.76% ($3.43) | Perf 3Y | 289.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -115.15% | Gross Margin | - | Volatility(W/M) | 4.74% 4.42% | Perf 5Y | 31.52% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.09 | EPS Q/Q | -301.43% | Profit Margin | - | RSI (14) | 43.27 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.09 | Sales Q/Q | - | SMA20 | -3.36% ($13.51) | Beta | 1.27 | Target Price | $17.8 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/8/10 | SMA50 | -8.41% ($14.26) | Rel Volume | 0.9 | Prev Close | $13.23 |
| Employees | 112 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | -256.14% -98.27% | SMA200 | 23.24% ($10.6) | Avg Volume(3M) | 0.53M | Price | $13.06 |
| IPO | 2021/3/8 | Option/Short | Yes/Yes | Trades | 3961 | Volume | 475,361 | Change | -1.28% |
🔬 Alpha Tau Medical (DRTS) is a clinical-stage oncology company developing Diffusing Alpha-emitter Radiation Therapy (Alpha DaRT) technology for the treatment of solid tumors. Its approach involves radioactive sources implanted directly into the tumor that continuously release short-lived alpha-emitting atoms to destroy the tumor locally. The company is expanding its clinical trials to include a range of solid tumor indications, including skin cancer.
Over the past 1 year, on the higher side
17% below its 1-year high.
Traded about as much as usual. That is 90% of its average volume.
DRTS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -80.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +31.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IZRL ARK Israel Innovative Technology ETF 0.02% 
EHLS Even Herd Long Short ETF <0.01% It ranks #143 of 597 in the industry
Based on market cap of $1B.
SLN#141 Silence Therapeutics Plc ADR $1B PER - 
SNDX#142 Syndax Pharmaceuticals Inc $1B PER - DRTS#143 Alpha Tau Medical Ltd $1B PER - 
RAPP#144 Rapport Therapeutics Inc $1B PER - 
VSTM#145 Verastem Inc $1B PER - 
FAQ
What kind of company is DRTS?
DRTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DRTS?
The market cap of DRTS is approximately $1.2B, ranking 2,437 within its sector.
What is the 52-week high and low for DRTS?
DRTS has recorded a 52-week high of $15.79 and a low of $3.43.
